AstraZeneca (China): Promoting Social Innovation with Holistic Disease Management Solutions Throughout the Patient Journey

Wang Hong and Dominique Turpin
Additional contact information
Wang Hong: China Europe International Business School
Dominique Turpin: China Europe International Business School

A chapter in China-Focused Cases, 2025, pp 119-136 from Springer

Abstract: Abstract On February 10, 2022, AstraZeneca (“AZ”), a global pharmaceutical giant, announced its FY2021 results. Total revenue for 2021 was up 41% to US$ 37.41 billion, of which AstraZeneca China (“AZ-China”) contributed some US$ 6 billion as it continued to outperform other pharmaceutical multinationals in China.

Date: 2025
References: Add references at CitEc
Citations:

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:sprchp:978-981-97-8580-3_8

Ordering information: This item can be ordered from
http://www.springer.com/9789819785803

DOI: 10.1007/978-981-97-8580-3_8

Access Statistics for this chapter

More chapters in Springer Books from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().